171 related articles for article (PubMed ID: 33399181)
1. Comment on: The current practice of using angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers in diabetic hypertensive and non-hypertensive patients. Is there a room for vitamin D?
Alsaeed A
Saudi Med J; 2021 Jan; 42(1):115. PubMed ID: 33399181
[TBL] [Abstract][Full Text] [Related]
2. Comment on: The current practice of using angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers in diabetic hypertensive and non-hypertensive patients. Is there a room for vitamin D?
Jawad AS
Saudi Med J; 2020 Dec; 41(12):1381. PubMed ID: 33294899
[TBL] [Abstract][Full Text] [Related]
3. The current practice of using angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers in diabetic hypertensive and non-hypertensive patients. Is there a room for vitamin D?
Sukkarieh HH; Bustami RT; Abdu MN; Khokhar AA; Salih AA; Abdalla HK
Saudi Med J; 2020 Oct; 41(10):1083-1089. PubMed ID: 33026049
[TBL] [Abstract][Full Text] [Related]
4. Angiotensin-converting enzyme inhibition or angiotensin receptor blockade in hypertensive diabetics?
Laverman G; Ruggenenti P; Remuzzi G
Curr Hypertens Rep; 2003 Oct; 5(5):364-7. PubMed ID: 12948427
[TBL] [Abstract][Full Text] [Related]
5. The role of angiotensin receptor blockers in diabetic nephropathy.
Sharma AM; Weir MR
Postgrad Med; 2011 May; 123(3):109-21. PubMed ID: 21566421
[TBL] [Abstract][Full Text] [Related]
6. Single versus dual blockade of the renin-angiotensin system (angiotensin-converting enzyme inhibitors and/or angiotensin II receptor blockers) in diabetic nephropathy.
Jacobsen P; Rossing K; Parving HH
Curr Opin Nephrol Hypertens; 2004 May; 13(3):319-24. PubMed ID: 15073491
[TBL] [Abstract][Full Text] [Related]
7. [The effect of angiotensin-converting enzyme inhibitors on the progression of chronic renal failure].
Bernadet-Monrozies P; Rostaing L; Kamar N; Durand D
Presse Med; 2002 Nov; 31(36):1714-20. PubMed ID: 12467154
[TBL] [Abstract][Full Text] [Related]
8. Angiotensin-converting enzyme inhibitors versus angiotensin II receptor blockers for renal outcomes and mortality in diabetic kidney disease.
Jiang S; Fang J; Yu T; Li W
Eur J Intern Med; 2021 Mar; 85():127-129. PubMed ID: 33250340
[No Abstract] [Full Text] [Related]
9. Combination use of angiotensin converting enzyme inhibitors and angiotensin receptor blockers in diabetic kidney disease.
Stanton RC
Curr Diab Rep; 2013 Aug; 13(4):567-73. PubMed ID: 23653011
[TBL] [Abstract][Full Text] [Related]
10. Renoprotective effects of renin-angiotensin-aldosterone system blockers in type 2 diabetes: demystifying multiple treatment comparisons in a network meta-analysis.
Catalá-López F
Diabetologia; 2012 Sep; 55(9):2547-8; author reply 2549-50. PubMed ID: 22729654
[No Abstract] [Full Text] [Related]
11. In patients with chronic diabetic nephropathy, do angiotensin-converting enzyme inhibitors (ACEI) have greater renal protective effect as compared to angiotensin receptor blockers (ARB)?
Tucker S; Chen Y; Abell R
J Okla State Med Assoc; 2013 Jul; 106(7):294-5. PubMed ID: 24032256
[No Abstract] [Full Text] [Related]
12. Is there benefit in dual renin-angiotensin-aldosterone system blockade? No, yes and maybe: a guide for the perplexed.
Wong J
Diab Vasc Dis Res; 2013 May; 10(3):193-201. PubMed ID: 23349369
[TBL] [Abstract][Full Text] [Related]
13. [Significance of RAAS inhibition in diabetic nephropathy].
Tsuruya K; Toyonaga J
Nihon Rinsho; 2012 Jul; 70 Suppl 5():411-8. PubMed ID: 23156430
[No Abstract] [Full Text] [Related]
14. What is the role of direct renin inhibitors in the treatment of the hypertensive diabetic patient?
de la Sierra A; Salazar J
Adv Ther; 2011 Sep; 28(9):716-27. PubMed ID: 21809181
[TBL] [Abstract][Full Text] [Related]
15. Angiotensin-converting enzyme inhibitors and angiotensin receptor blockers for hypertension: are they equivalent?
Kaplan NM
J Am Soc Hypertens; 2015 Aug; 9(8):582-3. PubMed ID: 26319536
[No Abstract] [Full Text] [Related]
16. Blockade of the renin-angiotensin system.
Cheung BM
Hong Kong Med J; 2002 Jun; 8(3):185-91. PubMed ID: 12055364
[TBL] [Abstract][Full Text] [Related]
17. Vitamin D protects against diabetic nephropathy: Evidence-based effectiveness and mechanism.
Hu X; Liu W; Yan Y; Liu H; Huang Q; Xiao Y; Gong Z; Du J
Eur J Pharmacol; 2019 Feb; 845():91-98. PubMed ID: 30287151
[TBL] [Abstract][Full Text] [Related]
18. Vitamin D deficiency: consequence or cause of CKD?
de Boer IH; Thadhani R
Clin J Am Soc Nephrol; 2013 Nov; 8(11):1844-6. PubMed ID: 24135217
[No Abstract] [Full Text] [Related]
19. Comparison of type 1 angiotensin II receptor blockers and angiotensin converting enzyme inhibitors in the treatment of hypertension.
Weber MA
J Hypertens Suppl; 1997 Dec; 15(6):S31-6. PubMed ID: 9493125
[TBL] [Abstract][Full Text] [Related]
20. ACE inhibitors or ARBs for diabetic nephropathy: the unrelenting debate.
Kota SK; Meher LK; Jammula S; Kota SK; Modi KD
Diabetes Metab Syndr; 2012; 6(4):215-7. PubMed ID: 23199543
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
